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Recombinant Iss as a Potential Vaccine for Avian Colibacillosis
Abstract
Avian pathogenic Escherichia coli (APEC) cause colibacillosis, a disease which is responsible for significant
losses in poultry. Control of colibacillosis is problematic due to the restricted availability of relevant
antimicrobial agents and to the frequent failure of vaccines to protect against the diverse range of APEC
serogroups causing disease in birds. Previously, we reported that the increased serum survival gene (iss) is
strongly associated with APEC strains, but not with fecal commensal E. coli in birds, making iss and the outer
membrane protein it encodes (Iss) candidate targets for colibacillosis control procedures. Preliminary studies
in birds showed that their immunization with Iss fusion proteins protected against challenge with two of the
more-commonly occurring APEC serogroups (O2 and O78). Here, the potential of an Iss-based vaccine was
further examined by assessing its effectiveness against an additional and widely occurring APEC serogroup
(O1) and its ability to evoke both a serum and mucosal antibody response in immunized birds. In addition,
tissues of selected birds were subjected to histopathologic examination in an effort to better characterize the
protective response afforded by immunization with this vaccine. Iss fusion proteins were administered
intramuscularly to four groups of 2-wk-old broiler chickens. At 2 wk postimmunization, chickens were
challenged with APEC strains of the O1, O2, or O78 serogroups. One week after challenge, chickens were
euthanatized, necropsied, any lesions consistent with colibacillosis were scored, and tissues from these birds
were taken aseptically. Sera were collected pre-immunization, postimmunization, and post-challenge, and
antibody titers to Iss were determined by enzyme-linked immunosorbent assay (ELISA). Also, air sac
washings were collected to determine the mucosal antibody response to Iss by ELISA. During the observation
period following challenge, 3/12 nonimmunized chickens, 1/12 chickens immunized with 10 µg of GST-Iss,
and 1/12 chickens immunized with 50 µg of GST-Iss died when challenged with the O78 strain. No other
deaths occurred. Immunized chickens produced a serum and mucosal antibody response to Iss and had
significantly lower lesion scores than nonimmunized chickens following challenge, regardless of the challenge
strain. This study expands on our previous report of the value of Iss as an immunoprotective antigen and
demonstrates that immunization with Iss can provide significant protection of chickens against challenge with
three different E. coli strains.
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SUMMARY. Avian pathogenic Escherichia coli (APEC) cause colibacillosis, a disease which is responsible for significant losses in
poultry. Control of colibacillosis is problematic due to the restricted availability of relevant antimicrobial agents and to the frequent
failure of vaccines to protect against the diverse range of APEC serogroups causing disease in birds. Previously, we reported that the
increased serum survival gene (iss) is strongly associated with APEC strains, but not with fecal commensal E. coli in birds, making iss
and the outer membrane protein it encodes (Iss) candidate targets for colibacillosis control procedures. Preliminary studies in birds
showed that their immunization with Iss fusion proteins protected against challenge with two of the more-commonly occurring
APEC serogroups (O2 and O78). Here, the potential of an Iss-based vaccine was further examined by assessing its effectiveness
against an additional and widely occurring APEC serogroup (O1) and its ability to evoke both a serum and mucosal antibody
response in immunized birds. In addition, tissues of selected birds were subjected to histopathologic examination in an effort to
better characterize the protective response afforded by immunization with this vaccine. Iss fusion proteins were administered
intramuscularly to four groups of 2-wk-old broiler chickens. At 2 wk postimmunization, chickens were challenged with APEC
strains of the O1, O2, or O78 serogroups. One week after challenge, chickens were euthanatized, necropsied, any lesions consistent
with colibacillosis were scored, and tissues from these birds were taken aseptically. Sera were collected pre-immunization,
postimmunization, and post-challenge, and antibody titers to Iss were determined by enzyme-linked immunosorbent assay
(ELISA). Also, air sac washings were collected to determine the mucosal antibody response to Iss by ELISA. During the observation
period following challenge, 3/12 nonimmunized chickens, 1/12 chickens immunized with 10 mg of GST-Iss, and 1/12 chickens
immunized with 50 mg of GST-Iss died when challenged with the O78 strain. No other deaths occurred. Immunized chickens
produced a serum and mucosal antibody response to Iss and had significantly lower lesion scores than nonimmunized
chickens following challenge, regardless of the challenge strain. This study expands on our previous report of the value of Iss as an
immunoprotective antigen and demonstrates that immunization with Iss can provide significant protection of chickens against
challenge with three different E. coli strains.
RESUMEN. La cepa recombinante Iss como una posible vacuna contra la colibacilosis aviar.
La Escherichia coli patoge´nica aviar (APEC) causa la colibacilosis, una enfermedad que es responsable de importantes pe´rdidas en
la avicultura. El control de la colibacilosis es problema´tico debido a la limitada disponibilidad de agentes antimicrobianos relevantes
y a la frecuente falla de las vacunas para proteger contra el diverso rango de serogrupos de APEC que causan enfermedades en las
aves. Anteriormente, se reporto´ que el gene de la supervivencia aumentada contra suero (Iss) esta´ fuertemente asociado con las cepas
APEC, pero no con las cepas de E. coli comensales en materia fecal de las aves, favoreciendo que el gene iss y la proteı´na de
membrana externa que codifica este gene (Iss) como los candidatos adecuados para procedimientos de control contra la
colibacilosis. Los estudios preliminares en las aves mostraron que la inmunizacio´n con proteı´nas de fusio´n Iss protegieron contra el
desafı´o con dos de los serogrupos APEC que ma´s comu´nmente se presentan (O2 y O78). En este caso, el potencial de una vacuna
basada en Iss se examino´ mediante la evaluacio´n de su eficacia contra un serogrupo de APEC adicional y que se presenta
ampliamente, (O1) y tambie´n se analizo´ su capacidad para evocar una respuesta de anticuerpos en el suero y en las mucosas en las
aves inmunizadas. Adema´s, los tejidos de las aves seleccionadas fueron sometidos a examen histopatolo´gico con el fin de caracterizar
mejor la respuesta de proteccio´n proporcionada por la inmunizacio´n con esta vacuna. Las proteı´nas de fusio´n Iss fueron
administradas por vı´a intramuscular a cuatro grupos de pollos de engorde de dos semanas de edad. A las dos semanas
postinmunizacio´n, los pollos fueron desafiados con cepas APEC de los serogrupos O1, O2, o´ O78. Una semana despue´s del desafı´o,
se practico´ la eutanasia de los pollos y se realizo´ la necropsia, las lesiones compatibles con colibacilosis fueron registradas, y los
tejidos de estas aves se recolectaron en forma ase´ptica. Muestras de suero fueron recolectadas antes de la vacunacio´n,
postinmunizacio´n, y despue´s del desafı´o, y los tı´tulos de anticuerpos contra la ISS se determinaron mediante un ensayo de
inmunoabsorcio´n con enzimas ligadas (ELISA). Adema´s, se recolecto´ el aire lavado de los sacos para determinar la respuesta de
anticuerpos contra Iss en la mucosa por ELISA. Durante el perı´odo de observacio´n posterior al desafı´o, 3 de 12 gallinas
inmunizadas, 1 de 12 pollos inmunizados con 10 mg de GST-Iss, y 1 de 12 pollos inmunizados con 50 mg de GST-Iss murieron
despue´s de ser desafiados con la cepa O78. No se presento´ ma´s mortalidad. Los pollos vacunados produjeron una respuesta de
anticuerpos en suero y en las mucosas contra Iss y mostraron puntuaciones ma´s bajas en las lesiones, en comparacio´n con los pollos
no inmunizados y que fueron desafiados, independientemente de la cepa de desafı´o. Este estudio amplı´a el reporte previo sobre el
valor de la proteı´na Iss como un antı´geno inmunoprotector y demuestra que la inmunizacio´n con la Iss puede proporcionar una
importante proteccio´n en los pollos contra el desafı´o con tres cepas diferentes de E. coli.
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Abbreviations: APEC5 avian pathogenic Escherichia coli; ELISA5 enzyme-linked immunosorbant assay; ExPEC5 extraintest-
inal pathogenic E. coli; GST5 glutathione-S-transferase; GST-Iss5 glutathione-S-transferase-Iss (the fusion protein);
HICS5 hyperimmune chicken sera; IPTG5 isopropyl-b-D-thiogalactopyranoside; NMEC5 neonatal meningitis E. coli;
PBS5 phosphate-buffered saline; PBSt5 phosphate-buffered saline with 0.05% TweenH 20; SPF5 specific-pathogen-free;
UPEC5 uropathogenic E. coli
Avian pathogenic Escherichia coli (APEC), the causative agent of
colibacillosis, is a major problem for the poultry industry in the
United States, resulting in significant losses annually (3). Addition-
ally, recent reports, providing evidence of a link between APEC-
contaminated poultry (21) and extraintestinal pathogenic E. coli
(ExPEC)-caused neonatal meningitis (24,44) and urinary tract
infections in human beings (24,39), suggest that control of avian
colibacillosis may have a beneficial impact on both avian and human
health. Control of colibacillosis is problematic, with the increased
restrictions on the use of antimicrobial agents in poultry making
vaccine-based control, where appropriate, increasingly desirable.
Unfortunately, vaccine-based control has proven difficult, to date, as
APECs are serotypically diverse with vaccines frequently failing to
protect against all but homologous challenge. Thus, identification of
vaccine targets, occurring among APECs, is an important step in the
development of useful colibacillosis vaccines that will have
widespread utility. Here, we evaluate an outer membrane protein
(Iss)-based vaccine for its ability to elicit protection in chickens
against heterologous challenge with APEC of three of the most
prominent serogroups implicated in avian colibacillosis, including
serogroups O1, O2, and O78 (40).
The increased serum survival gene iss (5,7,8,9,10,12,17,34,35,48),
described for its contribution to E. coli’s complement resistance
(5,8,9), was significantly more likely to occur in APEC than it was in
E. coli isolated from the feces of apparently healthy chickens (37,40).
The gene is found in most APEC regardless of its host type of
origin, lesion of origin, or serogroup (40) and is linked to large,
transmissible virulence plasmids which appear to be the defining
trait of the APEC pathotype (23,40). Iss, the protein it encodes
(4,16), occurs in APEC’s outer membrane where it is readily
accessible to the host defenses (31). This strong association between
iss and APEC, along with outer membrane location of Iss, suggested
that iss-centric strategies might be useful in colibacillosis control.
Previously, we evaluated the potential of a recombinant Iss fusion
protein to elicit a protective response in chickens against APEC
challenge (30). In this pilot study, chickens immunized with
glutathione-S-transferase-Iss (GST-Iss) were able to produce serum
antibody titers against GST-Iss and Iss that were significantly
different from nonimmunized controls. Also, this Iss-based vaccine
elicited a significant immunoprotective response to challenge with
two different APEC strains, as compared to nonimmunized controls,
with lower vaccine doses offering better protection than higher
doses. Such results suggested that Iss vaccines might be useful in
protecting against APEC infections in birds. However, this pilot
study did have limitations. The previous study did not take into
account any vaccine-associated immunopathology that could have
contributed to the lesions observed. Such pathologic changes might
be dose related, providing an explanation for the ‘apparent’ inverse
relationship between immunoprotection and vaccine dose. Also, in
the initial pilot study, mucosal antibody responses were not assessed.
Here, we sought to further study this vaccine and the protection it
provides against colibacillosis by challenging vaccinates and control
chickens with one of three common APEC serogroups implicated in
disease and by monitoring the mucosal and serum anti-Iss antibody
levels and histopathologic changes of the challenged animals. In this
way, we hope to better characterize Iss’ utility as an anticolibacillosis
vaccine.
MATERIALS AND METHODS
Bacterial strains and plasmids. Strains used were E. coli BL21 (DE3)
(Stratagene, La Jolla, CA), APEC strains APEC O1 (O1:K1) (19),
APEC O2 (O2:K2) (22), and x7122 (O78:K80) (38). Escherichia coli
BL21 was used for expression of GST-Iss while APEC O1, APEC O2,
and x7122 were used in experimental challenges. All strains were
maintained on Luria-Bertani agar (Difco, Detroit, MI) with ampicillin
(100 mg/ml; Amresco, Solon, OH) where appropriate. pGEX-6P-3
(Pharmacia Biotech, Piscataway, NJ), a plasmid expression vector
designed for production of proteins fused to GST, was used in these
studies. pLN330 is composed of pGEX-6P-3 with the iss gene sequence
(GenBank accession number AF0422279) without the coding region for
the signal sequence (the first 72 nucleotides of iss) (13). Using pLN330,
Iss protein fused to glutathione S-transferase (5GST-Iss) can be
expressed in E. coli BL21.
Expression and purification of Iss fusion proteins. Expression of
GST-Iss from pLN330 was induced with isopropyl-b-D-
thiogalactopyranoside (IPTG) as previously described (13). Induced
cells were lysed with B-PER Bacterial Protein Extraction Reagent
(Pierce, Rockford, IL) according to manufacturer’s instructions.
Inclusion bodies containing GST-Iss were solubilized with Inclusion
Body Solubilization Reagent (Pierce) according to manufacturer
protocols. The protein was refolded by dialysis against decreasing
concentrations of urea and finally against Tris buffer (25mM Tris-HCl,
150 mM NaCl, pH 7.5). Purification of GST-Iss and Iss was achieved
through use of an affinity matrix. The refolded protein was combined
with a 50% slurry of glutathione sepharose 4B beads (Pharmacia,
Waukesha, WI) and incubated for 1 hr at 4 C. The mixture was added
to a 10-ml column and the ‘‘flow through’’ collected. The column was
washed three times with phosphate-buffered saline (PBS). For GST-Iss
purification, the fusion protein was eluted with glutathione elution
buffer (10 mM glutathione, 50 mM Tris, pH 8.0). For Iss purification,
sepharose beads with bound fusion protein were resuspended in
PreScissionTM cleavage buffer (50 mM Tris-HCl, pH 7.0, 150 mM
NaCl, 1 mM EDTA, 1mM dithiothreitol [Pharmacia]). The fusion
protein was cleaved using PreScission protease (Pharmacia). The mixture
was added to a 10-ml column and Iss was eluted with cleavage buffer.
Chickens. Five, 2-wk-old specific-pathogen-free (SPF) leghorn
chickens and 240 1-day-old broiler chickens were obtained from
Charles River Laboratories (Charles River SPAFAS, North Franklin,
CT) and a commercial farm, respectively. SPF chickens were used to
obtain hyperimmune and negative control sera for enzyme-linked
immunosorbant assay (ELISA) experiments while broilers were used for
challenge studies. All chickens were housed in the Laboratory Animal
Resources building (Iowa State University, Ames, IA), given access to
food and water ad libitum, and handled according to Institution of
Animal Care and Use protocols. SPF chickens were placed in stainless
steel HEPA-filtered negative-pressure isolation rooms prior to
vaccination.
Immunization of broiler chickens. Broiler chickens were random-
ized, banded, and divided into four groups of 60 chickens with each bird
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receiving a unique number. At 2 wk of age, each bird was given 0.5 ml
(100 mg/ml) of QuilATM adjuvant (Superfos Biosector a/s, Freder-
ikssund, Denmark) in PBS, containing either 50 mg, 10 mg, 2 mg, or 0 mg
(PBS control) of GST-Iss, intramuscularly into the thigh.
Challenge experiment. Two weeks following immunization, 12
broiler chickens from each group were separated into four different
rooms and were subjected to challenge with an APEC strain. Each
chicken in the same room was challenged with the same strain. Chickens
in rooms 1, 2, and 3 received 0.1 ml (107 colony-forming units) of
APEC O1, APEC O2, or x7122, respectively, into the left caudal
thoracic air sac. As a negative control, chickens in room 4 received 0.1 ml
of PBS, mixed with the adjuvant, via the same route. Chickens were
observed for signs of disease for 7 days following challenge. Chickens
that died were necropsied and examined for lesions consistent with
colibacillosis. In addition, samples from air sacs, pericardium, and liver
were collected for bacterial isolation on MacConkey agar and in brain
heart infusion broth. After the observation period, survivors were
euthanatized with SleepawayH (Fort Dodge Laboratories, Fort Dodge,
IA), necropsied, examined for lesions consistent with colibacillosis, and
samples were taken as before. Lesions consistent with colibacillosis,
including mild or severe airsacculitis, perihepatitis, pericarditis, or death,
were scored according to the established system outlined in Table 1
(36). In an effort to keep lesion scoring as objective as possible, the
researchers who were performing the necropsy and scoring lesions were
not told to which groups the birds belonged. Each bird was scored by
two people independently and then scores were compared for
consistency. Any scores that were not the same were scored by a third
individual. If the third score matched one of the first two scores, that
score was recorded.
Collection of sera. Blood was collected from chickens before
immunization, 1 wk postimmunization, 2 wk postimmunization, and
1 wk postchallenge. Sera were collected from blood samples and stored
at 220 C for later evaluation using ELISA.
Collection of air sac washings. Air sacs from the immunized and
control chickens were washed with 1 ml of sterile PBS, centrifuged, and the
supernatant from each was stored at220 C for later evaluation using ELISA.
Production of control sera for ELISA. Hyperimmune chicken sera
(HICS) were raised against Iss in five SPF chickens. At the age of 2 mo,
each chicken was given a 0.5-ml suspension, intramuscularly, containing
50 mg of QuilA adjuvant and 50 mg of GST-Iss. Two booster injections
were given 2 wk apart via the same route. Chickens were bled 10 days
after the last immunization to collect HICS. Sera collected before
immunization served as the negative control in the ELISA assays.
ELISA. Sera collected from the challenge experiment were used to
perform the antigen-specific ELISA to determine the presence of
antibodies specific for Iss using methods previously described (30). Iss
coating antigen was diluted to 2–10 mg/ml in coating buffer (0.02 M
carbonate, 0.03 M bicarbonate, pH 9.6); 100 ml of the coating antigen
was added to each of the wells of a 96-well plate. The plate was covered
and incubated overnight at 4 C. The plate was then washed three times
with coating buffer. Wells were blocked with 200 ml of a 3% solution of
bovine serum albumin, dissolved in coating buffer, and incubated for
3 hr at room temperature to prevent non-specific binding. The blocker
was removed and the trays were washed three times with PBS with
0.05% Tween 20 (PBSt).
To determine antibody titers, sera were serially diluted in PBSt. HICS
was used as a positive control and PBSt was used as a negative control.
One-hundred microliter samples of each dilution were dispensed into
the wells of the plate. For each ELISA, trays were incubated for 1 hr at
room temperature. Following incubation with primary antibody, the
antibody was removed and the plates were washed five times with PBSt.
One-hundred microliters of alkaline phosphatase-conjugated goat anti-
chicken IgG (Sigma, St. Louis, MO) was added to each well. Plates were
washed seven times with PBSt and developed with p-nitrophenyl
phosphate in diethanolamine buffer. Color development was recorded at
405 nm using an automated ELISA plate reader (Biomek Plate Reader;
Beckman, Fullerton, CA). To determine the presence of mucosal
antibodies specific for Iss, the ELISA was performed in the same manner
except that undiluted air-sac washings were used. However, total protein
concentrations of each washing were determined and samples were
normalized to relatively equal protein concentrations for use in ELISA.
Histopathology. Samples from air sacs, pericardium, and liver of
necropsied chickens were collected and processed for light microscopy.
Tissues were fixed in 10% buffered formalin embedded in paraffin and
sectioned at 5 mm. Sections were stained with hematoxylin and eosin and
examined with light microscopy.
Biostatistics. Efficacy of the vaccine against challenge was evaluated
by the number of deaths and average lesion scores of vaccinates as
compared to unvaccinated chickens. Data were analyzed by the Fisher’s
least significant difference multiple comparison test with the significance
level set at P # 0.05.
RESULTS
GST-Iss was expressed from E. coli BL21 (DE3) containing
pLN330 by induction with IPTG. Cells were then harvested and
lysed. Inclusion bodies were solubilized, and the fusion protein
was purified by affinity chromatography (30) and used as an
immunogen. Also, recombinant Iss was produced for use with
ELISA to determine serum titers. Iss was cleaved from its fusion
partner with PreScission protease and the fusion partner was
removed by affinity chromatography (30).
Chickens immunized with GST-Iss were able to generate an
antibody immune response against Iss as compared to controls
(Fig. 1). All chickens that were immunized with GST-Iss had a
significant increase (P , 0.05) in serum IgG antibody titer
compared to chickens that received PBS. After challenge with
APEC, all chickens showed an increase in serum anti-Iss IgG titers,
regardless of the challenge strain. No significant difference was
observed in titer levels of chickens challenged with different APEC
strains. Chickens that were immunized with GST-Iss also showed a
significantly greater (P , 0.05) anti-Iss IgA and IgG response in air
sac mucosa samples (Fig. 2). Also, no significant difference was
observed in titer levels of chickens challenged with the different
E. coli strains.
During the observation period following challenge, 3/12
nonimmunized chickens, 1/12 chickens immunized with 10 mg of
GST-Iss, and 1/12 chickens immunized with 50 mg of GST-Iss died
when challenged with O78 strain x7122. No other deaths occurred.
Chickens had significantly lower lesion scores when immunized with
Table 1. Lesion scoring.A
Location and description Score
Air sacs
Normal 0
Mild cloudiness and thickness 1
Moderate cloudiness and thickness accompanied by serous
exudates or fibrin spots
2
Extensive cloudiness and thickness accompanied by muco- or
fibrinopurulent exudate
3
Heart and pericardium
Normal 0
Turbid with extensive or cloudy fluid in the pericardial cavity 1
Marked pericarditis 2
Liver
Normal 0
Slight amount of fibrinous exudate 1
Marked perihepatitis 2
Recovery of E. coli from either air sacs, pericardial sac, or liver 1
AMaximum possible score 5 8.
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GST-Iss, regardless of dose level or challenge strain used, when
compared to controls (Table 2).
Macroscopic and microscopic lesions (or both) in the air sacs,
liver, and pericardium consistent with colisepticemia were evident in
some of the chickens that were challenged with E. coli. These lesions
were detected in chickens challenged with each of the different
APEC strains. Macroscopic lesions observed included thickened air
sacs with caseous exudate and yellowish, fibrinous membranes
covering the liver and the heart (Fig. 3). Histopathologic lesions
included heterophil and mononuclear cell infiltration, hyperplasia of
the epithelium, and the presence of necrotic foci in the air sacs, liver,
pericardium, and myocardium in varying combinations (Fig. 4).
One bird vaccinated with 50 mg of GST-Iss, but not challenged with
any of the challenge strains, showed lesions consistent with
colisepticemia. Bacterial cultures of the air sac, pericardium, liver,
and blood were all positive when cultured for E. coli.
DISCUSSION
Avian colibacillosis is a costly disease to the poultry industry,
accounting for multimillion-dollar losses annually (3). There is a
need for improved control of avian colibacillosis because current
control strategies, which focus on reducing predisposing conditions
among production chickens, have proven largely ineffective (3). In
addition, strategies that have controlled colibacillosis in the past may
not be as effective in the future, as recent studies in our lab show that
APECs are becoming more resistant to antimicrobials over time
(unpubl. data). Also, the use of antimicrobial agents in animal
production is under close scrutiny, with limitations being placed on
the use of some therapeutic agents in poultry production (10). Thus,
it seems likely that future control of colibacillosis by using vaccines
may prove increasingly desirable.
To date, vaccines designed to prevent avian colibacillosis have been
met with mixed results. Vaccines against various E. coli serogroups have
been produced (1,2,6,7,11,12,14,15,25,27,29,30,32,36,41,45,46,47).
The composition of these vaccines has been quite variable and has
included live, attenuated E. coli strains (1,25,29,36), inactivated E. coli
strains (11,12,32), active immunization with various E. coli antigens
(7,30,41,46,47), and passive immunization (2,6,26). While many of
these vaccines were effective against homologous challenge, they did
not offer broad-range protection against heterologous challenge.
Failure to protect against heterologous challenge may prove a critical
limitation of colibacillosis vaccines because of the diversity among
APECs (40).
Previously, we evaluated the potential of a recombinant Iss fusion
protein to elicit a protective response in chickens against APEC
challenge with O2 and O78 strains (30). Chickens immunized with
GST-Iss were able to produce antibody titers against GST-Iss and Iss
that were significantly different from nonimmunized controls. Also,
Iss did stimulate an immunoprotective response against challenge
with the different APEC strains. Paradoxically, lower doses seemed
to offer better protection than higher doses, a result we could not
explain adequately due to the limited scope of the study. However, at
that time, we felt that this result could be due to immunologic
unresponsiveness or immunopathology associated with excessively
high doses of antigen (28). In this study, we immunized broiler
chickens and challenged them with one of three different APEC
strains of the O1, O2, or O78 serogroups. These isolates were
different than those used in our previous study. Our results showed
that chickens immunized with GST-Iss at 2 wk of age were able to
mount a strong antibody response against the Iss portion of the
fusion protein that was significantly different from nonimmunized
controls. Also, when nonimmunized controls were subsequently
challenged with an iss+ APEC strain, anti-Iss antibody titers
increased to the levels of those seen in immunized chickens,
confirming our previous observation that Iss is surface-exposed in
APEC, where it interacts with the immune system during infection.
Immunized chickens also showed a mucosal antibody response in the
air sacs with both IgG and IgA isotypes, directed against Iss,
corresponding to results seen in other studies (27). As colibacillosis
often begins as a respiratory disease, an effective immune response in
the mucosa of the air sacs is desirable. Histopathologic examination
of challenged birds revealed lesions consistent with colibacillosis.
These data, plus the fact that the challenge strains were cultured
from the lesions, indicate that the lesions observed were due to
APEC infection.
The average lesion scores for chickens immunized with GST-Iss
were significantly lower than nonimmunized controls for all dose
levels regardless of challenge strain. In our pilot study, lower doses of
the immunogen provided better protection against subsequent
challenge than did higher doses. The higher lesion score associated
with the higher doses of immunogen could be due to immunopa-
thology caused by the large levels of immunogen, thereby increasing
the lesions scores in those chickens that received the higher doses. In
the present study, while all doses significantly lowered lesion scores
compared to controls, there was no consensus as to which dose level
offered the best protection. For the three groups of immunized
chickens that were given PBS instead of a challenge strain, no lesions
Fig. 2. Mucosal antibody levels as determined by ELISA of air sac
washings 2 wk postimmunization. Columns represent the means for
each group, bars represent standard deviations.
Fig. 1. Immunogenicity of Iss in chickens. Columns represent the
means for each group, bars represent standard deviations.
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consistent with colibacillosis were seen for chickens immunized with
2 mg and 10 mg, while one bird that received 50 mg of immunogen
showed mild lesions consistent with colibacillosis, resulting in a
small average lesion score that was not significantly different (P ,
0.05) than controls. The average lesion scores are interesting, as they
do not confirm the results of our previous study in regard to vaccine
efficacy and its relationship to dosage. We had hypothesized that the
higher lesions scores associated with the higher Iss doses were due to
immunization-caused pathology; we were unable to confirm that
hypothesis in the current study.
While this study was unable to account for the results obtained
previously, the data are useful in further characterization of Iss as a
potential vaccine candidate. Here, immunization with a GST-Iss
fusion was shown to provide significant protection against three
different APEC isolates of different serogroups. The ability to
protect against heterologous challenge is critical, as APECs are very
diverse (37,40). Thus, the fact that the Iss fusion protein was
effective against all three serotypes tested is promising, as the
challenge isolates used in this study are quite diverse in their content
of virulence factors and antigens (19,20,22,38). Also, the histopa-
thology found in nonimmunized, challenged chickens shows that the
gross lesions seen in these chickens were due to APEC infection.
This histopathology was not seen in immunized chickens, suggesting
that immunization with the Iss fusion protein not only provided
protection against challenge, it lacked an evident adverse effect.
Finally, because the Iss fusion protein provided a mucosal antibody
response in the air sac, we suspect that an Iss-based vaccine might
prove effective in preventing avian colibacillosis. Future field trials
will be beneficial in assessing this supposition.
Overall, our current study demonstrates that the Iss fusion protein
is capable of eliciting protection of chickens against challenge with
different APEC strains. While these results are encouraging, our
study did have limitations. While vaccinates demonstrated protec-
tion against three of the more common serogroups occurring in
APEC (43), many other serogroups are known to cause disease in
chickens (40). Thus, future studies will need to assess the vaccine for
its ability to evoke protection against multiple APEC strains.
However, because the O1, O2, and O78 serogroups are among the
more commonly occurring serogroups causing colibacillosis, signif-
icant and important protection of birds might follow Iss vaccination
whether or not it protected against other serogroups. Also, while iss is
one of the most widely occurring traits among APECs (37,40), a
small subset of E. coli isolated from avian colibacillosis lack iss
(37,40), suggesting that an Iss vaccine would not protect chickens
from infections with all APECs. However, coverage need not be total
to provide significant benefit to flock health.
Therefore, an efficacious and cost-effective Iss-based vaccine,
protective against APEC O1, O2, and O78 serogroups, could prove
beneficial to the poultry industry. It might also, in turn, be beneficial
to human health. Recently, researchers have explored the possibility
that there is a link between APEC and human ExPEC, including
uropathogenic E. coli (UPEC) and neonatal meningitis E. coli
(NMEC). When Rodriguez-Siek et al. (39) compared traits of APEC
and human UPEC, they found that these two groups overlapped in
their serogroups, phylogenetic groups, and virulence genotypes
including in their possession of iss. Johnson et al. (19,22) showed
that iss occurs on a conserved virulence cluster found on conjugative
ColV and ColBM plasmids of APEC isolates. Skyberg et al. (42)
found that transfer of these virulence plasmids to commensal E. coli
increased the recipient strains’ ability to grow in human urine and to
colonize the kidney of mice. In order to follow up on this
observation, Johnson et al. (20) sequenced the entire genome of
APEC O1 (an O1:K1:H7 strain) and compared it to other known
E. coli genomes. The APEC O1 genome was greater than 95%
similar to the genomes of human ExPEC (20). Also, the APEC
genome was found to be very closely related to ExPEC strains UPEC
UTI89 and NMEC RS218, based on in silico multilocus sequence
typing (20). Others findings have confirmed these similarities. For
instance, when Moulin-Schouler et al. (33) compared O18:K1
ExPEC strains of human and avian origin for common virulence
factors and genetic relationship, they found that APEC and NMEC
Table 2. Average lesion score after immunization and challenge.A
Vaccine level (mg/dose)
Challenge strain
O1 O2 O78 PBS
50 0.167 (0.389)B 0.33 (0.65)B 1.27 (2.37)BC 0.2 (0.63)
10 0.167 (0.389)B 0.00 (0.00)B 1.27 (2.10)BD 0.0 (0.0)
2 0.90 (2.50)B 0.167 (0.58)B 1.27 (2.00)BD 0.0 (0.0)
PBS 2.38 (2.10) 1.36 (1.03) 4.09 (3.30) 0.0 (0.0)
AValues are means (standard deviations) with 12 chickens per group.
BSignificantly different (P , 0.05) from lesion score of chickens vaccinated with PBS and challenged with same strain.
CThree deaths occurred.
DOne death occurred.
Fig. 3. Colisepticemic lesions of an unvaccinated chicken challenged
with E. coli O78. (A) pericarditis; (B) airsacculitis; (C) perihepatitis. A
yellowish, fibrinous covering is present on the serosal surfaces of the air
sacs, heart, and liver.
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share several virulence factors and overlap in their phylogenetic
grouping. Also, in a study of over 1,000 ExPEC from human and
avian sources, Johnson et al. (24) found a mixed cluster of ExPEC
subpathotypes (APEC, NMEC, and UPEC) that shared much
overlap in their virulence genotypes and belonged to serogroups,
MLST types, and phylogenetic groups that typify human pathogens.
They regarded the isolates of this mixed cluster as being potential
zoonotic pathogens. In addition to their similarities in chromosomal
virulence genes, most of these isolates harbored iss-containing
plasmids, suggesting that Iss-based vaccines might be efficacious in
protecting against infection with these organisms. Interestingly,
Tivendale et al.’s (44) further evaluation of members of this cluster
in avian and mammalian models of disease appears to have
confirmed their zoonotic potential. Thus, development of Iss-based
vaccines might prove beneficial to both avian and human health.
Indeed, development of a universal ExPEC vaccine could find a
broad spectrum of use, protecting against such human diseases as
septicemia, urinary tract infection, and meningitis and such avian
diseases as septicemia, airsacculitis, cellulitis, and peritonitis. Also,
such a vaccine might reduce the occurrence of ExPEC-caused
diseases in many other hosts such as felines, canines, swine, and
bovines, as ExPEC-caused diseases occur widely among various
animal hosts (18). Thus, future research to evaluate the protective
potential of Iss-based vaccines, as described here against ExPEC
infections in nonavian hosts, seems warranted.
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